Logo image of PLUR

PLURI INC (PLUR) Stock Fundamental Analysis

NASDAQ:PLUR - Nasdaq - US72942G2030 - Common Stock - Currency: USD

5.2  -0.21 (-3.88%)

After market: 5.1 -0.1 (-1.92%)

Fundamental Rating

2

Overall PLUR gets a fundamental rating of 2 out of 10. We evaluated PLUR against 556 industry peers in the Biotechnology industry. Both the profitability and financial health of PLUR have multiple concerns. PLUR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year PLUR has reported negative net income.
PLUR had a negative operating cash flow in the past year.
In the past 5 years PLUR always reported negative net income.
PLUR had a negative operating cash flow in each of the past 5 years.
PLUR Yearly Net Income VS EBIT VS OCF VS FCFPLUR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

PLUR has a Return On Assets of -55.37%. This is comparable to the rest of the industry: PLUR outperforms 46.04% of its industry peers.
Industry RankSector Rank
ROA -55.37%
ROE N/A
ROIC N/A
ROA(3y)-56.83%
ROA(5y)-53.66%
ROE(3y)-7370.79%
ROE(5y)-4450.32%
ROIC(3y)N/A
ROIC(5y)N/A
PLUR Yearly ROA, ROE, ROICPLUR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K

1.3 Margins

Looking at the Gross Margin, with a value of 52.13%, PLUR is in the better half of the industry, outperforming 76.98% of the companies in the same industry.
PLUR's Gross Margin has been stable in the last couple of years.
PLUR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 52.13%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y0.51%
PLUR Yearly Profit, Operating, Gross MarginsPLUR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K -100K

More info and screens

2

2. Health

2.1 Basic Checks

PLUR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PLUR has been increased compared to 1 year ago.
Compared to 5 years ago, PLUR has more shares outstanding
PLUR has a worse debt/assets ratio than last year.
PLUR Yearly Shares OutstandingPLUR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
PLUR Yearly Total Debt VS Total AssetsPLUR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -16.89, we must say that PLUR is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of PLUR (-16.89) is worse than 81.47% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -16.89
ROIC/WACCN/A
WACC8.08%
PLUR Yearly LT Debt VS Equity VS FCFPLUR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 4.81 indicates that PLUR has no problem at all paying its short term obligations.
PLUR has a Current ratio (4.81) which is in line with its industry peers.
PLUR has a Quick Ratio of 4.81. This indicates that PLUR is financially healthy and has no problem in meeting its short term obligations.
PLUR's Quick ratio of 4.81 is in line compared to the rest of the industry. PLUR outperforms 53.06% of its industry peers.
Industry RankSector Rank
Current Ratio 4.81
Quick Ratio 4.81
PLUR Yearly Current Assets VS Current LiabilitesPLUR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

6

3. Growth

3.1 Past

PLUR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.02%, which is quite good.
The Revenue has grown by 203.23% in the past year. This is a very strong growth!
Measured over the past years, PLUR shows a very strong growth in Revenue. The Revenue has been growing by 43.27% on average per year.
EPS 1Y (TTM)14.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.28%
Revenue 1Y (TTM)203.23%
Revenue growth 3YN/A
Revenue growth 5Y43.27%
Sales Q2Q%501.41%

3.2 Future

PLUR is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -22.20% yearly.
PLUR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 254.68% yearly.
EPS Next Y-156.25%
EPS Next 2Y-46.77%
EPS Next 3Y-22.2%
EPS Next 5YN/A
Revenue Next Year472.39%
Revenue Next 2Y350.32%
Revenue Next 3Y254.68%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PLUR Yearly Revenue VS EstimatesPLUR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2018 2019 2020 2022 2023 2024 2025 2026 2027 5M 10M
PLUR Yearly EPS VS EstimatesPLUR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PLUR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PLUR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PLUR Price Earnings VS Forward Price EarningsPLUR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PLUR Per share dataPLUR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

A cheap valuation may be justified as PLUR's earnings are expected to decrease with -22.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-46.77%
EPS Next 3Y-22.2%

More info and screens

0

5. Dividend

5.1 Amount

PLUR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PLURI INC

NASDAQ:PLUR (7/18/2025, 8:04:11 PM)

After market: 5.1 -0.1 (-1.92%)

5.2

-0.21 (-3.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07
Earnings (Next)09-16 2025-09-16/amc
Inst Owners19.43%
Inst Owner Change0%
Ins Owners13.25%
Ins Owner Change36.05%
Market Cap40.92M
Analysts82.86
Price Target12.24 (135.38%)
Short Float %0.58%
Short Ratio0.76
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)200%
PT rev (3m)200%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)2.38%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 39.58
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.61
EYN/A
EPS(NY)-2.64
Fwd EYN/A
FCF(TTM)-2.31
FCFYN/A
OCF(TTM)-2.2
OCFYN/A
SpS0.13
BVpS-0.57
TBVpS-0.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -55.37%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 52.13%
FCFM N/A
ROA(3y)-56.83%
ROA(5y)-53.66%
ROE(3y)-7370.79%
ROE(5y)-4450.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y0.51%
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 340.98%
Cap/Sales 87.72%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.81
Quick Ratio 4.81
Altman-Z -16.89
F-Score3
WACC8.08%
ROIC/WACCN/A
Cap/Depr(3y)75.54%
Cap/Depr(5y)54.21%
Cap/Sales(3y)103.34%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.28%
EPS Next Y-156.25%
EPS Next 2Y-46.77%
EPS Next 3Y-22.2%
EPS Next 5YN/A
Revenue 1Y (TTM)203.23%
Revenue growth 3YN/A
Revenue growth 5Y43.27%
Sales Q2Q%501.41%
Revenue Next Year472.39%
Revenue Next 2Y350.32%
Revenue Next 3Y254.68%
Revenue Next 5YN/A
EBIT growth 1Y4.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y36.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.03%
OCF growth 3YN/A
OCF growth 5YN/A